EasyJet Rebuffs Takeover as Merck Targets Bio-Techne Acquisition

EasyJet confirmed it remains in discussions with Castlelake despite dismissing the private equity firm’s fourth takeover attempt. The airline maintains that the offer failed to reflect its true market value, opting to continue its independent strategy rather than fold under the current valuation.

In the life sciences sector, Merck is aggressively expanding its footprint by securing the $11.3 billion purchase of Bio-Techne. This deal represents a strategic shift for the German company, aimed at deepening its technical capabilities and market reach. Meanwhile, regulatory pressures are mounting elsewhere: Ryanair is revising its family seating fee structure following a formal inquiry by UK authorities. On the domestic political front, Manchester Mayor Andy Burnham is moving to formalize a dedicated devolution department, a structural change designed to challenge existing Treasury control and accelerate regional economic growth.